Search results
Results from the WOW.Com Content Network
XLR-11 (5"-fluoro-UR-144 or 5F-UR-144) is a drug that acts as a potent agonist for the cannabinoid receptors CB 1 and CB 2 with EC 50 values of 98 nM and 83 nM ...
Urine contained 2.1 μg/L for the metabolite, and a detection below level of quantification for MDMB-4en-PINACA itself. [ 23 ] Adulterated Cannabis products in Europe that have been laced with MDMB-4en-PINACA have contained 0.3 to 4.6 μg/mg in seized flower samples and 1.7 to 7.2 μg/mg in hash/or other extract samples.
AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor. [3] It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University .
ADB-5'Br-BUTINACA (ADB-B-5Br-INACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug, [1] first detected in Philadelphia in the US in May 2022, [2] and subsequently found in South Korea, [3] Portugal and Sweden. [4]
MDA-19 binds to human CB 2 receptors at K i = 43.3 ± 10.3 nM and human CB 1 receptors at K i = 162.4 ± 7.6 nM and functions as an agonist in human cannabinoid receptors but functions differently in rat cannabinoid receptors binding to rat cannabinoid CB 2 receptors at K i = 16.3 ± 2.1 and CB 1 receptors at K i = 1130 ± 574 nM binding to rat CB 1 receptors 6.9× weaker than human CB 1 ...
AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the ...
4F-MDMB-BINACA (also known as MDMB-4F-BINACA, [2] 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family. [3] It should not be confused with the amantadine analogue 4F-ABINACA. It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018.
Compared to THC, which is a partial agonist at CB 1 receptors, JWH-018, and many synthetic cannabinoids, are full agonists. JWH-018 may cause intense anxiety, agitation, and in rare cases, has been assumed to have been the cause of seizures and convulsions. JWH-018 and analogs of it may present serious dangers to the user when used to excess. [22]